Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | — |
The patient received RabAvert vaccine on day 13 instead of day 14; Case reference number US-BN-2025-001601 is a spontaneous case initially received from a consumer via agency (reference number: USBAV25-2384) on 25-Sep-2025 and concerns a male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient had exposure to the animal. On an unknown date, unknown time after animal exposure, the patient received the first dose of RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, route or site of administration for postexposure prophylaxis. On an unknown date, unknown time after animal exposure, as reported the patient on day 13 instead 14, the patient received the dose of RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) for postexposure prophylaxis. (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to RabAvert. No further information was provided.; Reporter's Comments: This case concerns a male patient of unspecified age. As reported, the patient had received second dose of RabAvert vaccine on day 13 instead of 14, for an indication of post exposure prophylaxis, which is considered as 'inappropriate schedule of product administered'. Inappropriate schedule of product administered is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any adverse events due to RabAvert. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a male patient of unspecified age. As reported, the patient had received second dose of RabAvert vaccine on day 13 instead of 14, for an indication of post exposure prophylaxis, which is considered as 'inappropriate schedule of product administered'. Inappropriate schedule of product administered is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any adverse events due to RabAvert. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE